---
title: "Eiko Lifesciences Ltd (540204) — Share Price, Financials & Analysis"
symbol: "540204"
company: "Eiko Lifesciences Ltd"
canonical: "https://tapetide.com/stocks/540204"
isin: "INE666Q01016"
nse_symbol: "NARENDRAINVESTMENTSLTD"
bse_code: "540204"
sector: "Chemicals"
industry: "Specialty Chemicals"
market_cap_cr: 65.69
generated_at: "2026-09-13T18:37:08.471Z"
---

# Eiko Lifesciences Ltd (540204)

Canonical page: https://tapetide.com/stocks/540204

## Company

- **NSE Symbol:** NARENDRAINVESTMENTSLTD
- **BSE Code:** 540204
- **ISIN:** INE666Q01016
- **Sector:** Chemicals
- **Industry:** Specialty Chemicals
- **Macro Sector:** Commodities
- **Stock Type:** EQUITY
- **Listed Since:** 2016-12-13
- **Face Value:** ₹10
- **F&O Eligible:** No
- **Website:** eikolifesciences.com

## About

Incorporated in 2021, Eiko LifeSciences 
Ltd manufacturing & sells Specialty 
 Chemical and Fine Chemicals[1]

## Latest Price

## Key Fundamentals

Observed at 2026-09-11T04:45:08.726467Z.

- **Market Cap:** ₹65.69 Cr
- **Classification:** Microcap
- **P/E (reported):** 11.8
- **EPS (TTM):** ₹3.49
- **EPS (reported):** ₹0.6
- **Book Value:** ₹45.32
- **Price to Book:** 1.01
- **Dividend Yield:** 0%
- **ROE:** 7.63%
- **ROCE:** 10.07%
- **Debt to Equity:** 0.07
- **Revenue (yearly):** ₹53.7 Cr
- **Net Income:** ₹5.3 Cr
- **EBITDA:** ₹8.4 Cr
- **52-Week High:** ₹64.44
- **52-Week Low:** ₹44.75
- **RSI (14):** 42.35

## Tapetide Score

- **Score:** 57 / 100
- **Score date:** 2026-09-04
- **Archetype:** Weak and Under Pressure
- **What it means:** Weak financials are the defining feature, and neither the valuation nor the trend reading is strong enough to offset them. Worth reading the risk flags and recent filings closely before anything else.
- **Pillar profile:** Quality: Weak · Valuation: Fair · Momentum: Falling
- **Percentile:** 77.8 (of 4473 scored stocks)
- **Confidence:** 98%
- **Data coverage:** 95%

| Pillar | Score | Weight |
| --- | --- | --- |
| financial health | 77.62 | 9% |
| growth | 92.14 | 9% |
| momentum | 47.21 | 12% |
| ownership | 50 | 24% |
| quality | 46.91 | 22% |
| valuation | 59.84 | 24% |

The Tapetide Score is decision-support only, not investment advice.

## Key Insights

### Strengths

- Company is almost debt free.
- Stock is trading at 0.95 times its book value
- Company is expected to give good quarter

### Weaknesses

- Though the company is reporting repeated profits, it is not paying out dividend
- Promoter holding is low: 39.9%

## Growth Rates

| Metric | QoQ | 1Y | 3Y | 5Y |
| --- | --- | --- | --- | --- |
| cash flow growth | — | -19.06% | 781.82% | 2.25% |
| ebitda margin growth | 0% | 72.96% | -136.15% | -8.68% |
| net income growth | 0% | 130.43% | -247.22% | — |
| revenue growth | -7.03% | 39.84% | 72.84% | 86.19% |
| roce | -0.47% | 86.83% | -105.83% | -33.58% |
| roe | 0.67% | 87.47% | -104.61% | 119.88% |

## Financial Statements

### Quarterly Results

All figures in ₹ crore unless the row name says otherwise.

| Item | Mar 2020 | Jun 2020 | Sep 2020 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| Sales | 0.62 | 0.56 | 0.84 | 10.75 | 8.16 | 7.49 | 11.27 | 10.71 | 11.67 | 11.98 | 18.34 | 16.75 |
| Expenses | 1.53 | 0.42 | 0.89 | 10.35 | 7.73 | 6.86 | 9.95 | 9.2 | 9.9 | 10.1 | 16.08 | 14.82 |
| Operating Profit | -0.91 | 0.14 | -0.05 | 0.4 | 0.43 | 0.63 | 1.32 | 1.51 | 1.77 | 1.88 | 2.26 | 1.93 |
| OPM % | -146.77 | 25 | -5.95 | 3.72 | 5.27 | 8.41 | 11.71 | 14.1 | 15.17 | 15.69 | 12.32 | 11.52 |
| Other Income | -0.04 | 0.05 | 0.01 | 0.26 | 0.13 | 0.12 | 0.64 | 0.27 | 0.3 | 0.35 | 0.13 | 0.45 |
| Interest | 0.03 | 0.01 | 0.1 | 0.03 | 0.04 | 0.03 | 0.07 | 0.05 | 0.1 | 0.07 | 0.12 | 0.13 |
| Depreciation | 0.05 | 0.04 | 0.04 | 0.17 | 0.16 | 0.16 | 0.25 | 0.25 | 0.26 | 0.26 | 0.25 | 0.25 |
| Profit before tax | -1.03 | 0.14 | -0.18 | 0.46 | 0.36 | 0.56 | 1.64 | 1.48 | 1.71 | 1.9 | 2.02 | 2 |
| Tax % | -28.16 | 28.57 | -22.22 | 26.09 | 27.78 | 25 | 23.78 | 25 | 24.56 | 24.74 | 25.74 | 24.5 |
| Net Profit | -0.74 | 0.1 | -0.13 | 0.37 | 0.28 | 0.42 | 1.25 | 1.11 | 1.29 | 1.43 | 1.5 | 1.51 |
| EPS in Rs | -0.64 | 0.09 | -0.08 | 0.3 | 0.22 | 0.33 | 0.84 | 0.66 | 0.79 | 0.88 | 0.91 | 0.91 |

### Profit & Loss

All figures in ₹ crore unless the row name says otherwise.

| Item | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2025 | Mar 2026 | TTM |
| --- | --- | --- | --- | --- | --- | --- |
| Sales | 2.36 | 4.27 | 10.4 | 37.66 | 52.57 | 58.74 |
| Expenses | 1.98 | 4.95 | 14.91 | 34.89 | 45.24 | 50.9 |
| Operating Profit | 0.38 | -0.68 | -4.51 | 2.77 | 7.33 | 7.84 |
| OPM % | 16.1 | -15.93 | -43.37 | 7.36 | 13.94 | 13.35 |
| Other Income | 0.04 | 0.04 | 0.01 | 1.2 | 1.16 | 1.23 |
| Interest | 0.09 | 0.19 | 0.24 | 0.17 | 0.36 | 0.42 |
| Depreciation | 0.08 | 0.17 | 0.19 | 0.74 | 1.02 | 1.02 |
| Profit before tax | 0.25 | -1 | -4.93 | 3.06 | 7.11 | 7.63 |
| Tax % | 20 | -21 | -26.77 | 24.51 | 25.18 | — |
| Net Profit | 0.2 | -0.78 | -3.62 | 2.32 | 5.32 | 5.73 |
| EPS in Rs | 0.31 | -0.69 | -2.98 | 1.86 | 3.71 | 3.49 |
| Dividend Payout % | 0 | 0 | 0 | 0 | 0 | — |

### Balance Sheet

All figures in ₹ crore unless the row name says otherwise.

| Item | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2025 | Mar 2026 |
| --- | --- | --- | --- | --- | --- |
| Equity Capital | 3.82 | 3.82 | 3.82 | 13.76 | 14.35 |
| Reserves | 1.74 | 1.1 | -0.87 | 43.03 | 54.44 |
| Borrowings | 1.74 | 1.37 | 1.61 | 2.76 | 4.73 |
| Other Liabilities | 3.66 | 3.01 | 7.49 | 6.56 | 15.85 |
| Total Liabilities | 10.96 | 9.3 | 12.05 | 66.11 | 89.37 |
| Fixed Assets | 1.68 | 1.71 | 1.75 | 23.12 | 22.1 |
| CWIP | 0 | 0 | 0 | 0 | 0 |
| Investments | 3.17 | 1.72 | 0.1 | 7.15 | 15.29 |
| Other Assets | 6.11 | 5.87 | 10.2 | 35.84 | 51.98 |
| Total Assets | 10.96 | 9.3 | 12.05 | 66.11 | 89.37 |

### Cash Flow

All figures in ₹ crore unless the row name says otherwise.

| Item | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2025 | Mar 2026 |
| --- | --- | --- | --- | --- | --- |
| Cash from Operating Activity | 0 | 0.16 | -0.33 | 2.78 | 2.25 |
| Cash from Investing Activity | 0 | -0.3 | -0.71 | -11.3 | -8.63 |
| Cash from Financing Activity | 0 | -0.55 | 0.95 | 6.96 | 8.21 |
| Net Cash Flow | 0 | -0.69 | -0.09 | -1.57 | 1.83 |
| Free Cash Flow | 0 | -0.04 | -0.56 | -7.51 | 2.25 |
| CFO/OP | 0 | -26 | 7 | 112 | 50 |

### Ratios

| Item | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2025 | Mar 2026 |
| --- | --- | --- | --- | --- | --- |
| Debtor Days | 225.81 | 73.51 | 41.41 | 104.58 | 140.39 |
| Inventory Days | 819.93 | 287.76 | 153.96 | 64.48 | 35.09 |
| Days Payable | 605.69 | 174.4 | 184.66 | 36.99 | 111.03 |
| Cash Conversion Cycle | 440.04 | 186.87 | 10.72 | 132.07 | 64.46 |
| Working Capital Days | 80.42 | -1.71 | -151.62 | 143.73 | 127.89 |
| ROCE % | — | -11.83 | -105.39 | — | 11.12 |

## Shareholding Pattern

### Quarterly

| Category | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| Promoters | 24.23% | 24.23% | 24.23% | 24.4% | 24.4% | 31.27% | 36.23% | 36.74% | 37.17% | 37.17% | 39.91% | 39.91% |
| FIIs | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% |
| DIIs | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% |
| Government | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% |
| Public | 54.94% | 54.06% | 51.62% | 48.92% | 49.05% | 44.97% | 44.38% | 44.35% | 43.37% | 43.38% | 41.69% | 42.34% |
| Others | 20.83% | 21.71% | 24.15% | 26.68% | 26.55% | 23.76% | 19.39% | 18.91% | 19.47% | 19.46% | 18.41% | 17.76% |
| No. of Shareholders | 2722 | 2637 | 3000 | 2938 | 3140 | 3456 | 3336 | 3322 | 3150 | 3092 | 2969 | 3019 |

## Technical Indicators

Derived from daily closing prices and recomputed each trading session; values move with the market.

- **Overall Signal:** Strong Sell
- **Buy / Neutral / Sell:** 2 / 5 / 12

### Moving Averages — summary: **Strong Sell**

| Indicator | Value | Signal |
| --- | --- | --- |
| SMA (10) | 46.33 | Sell |
| EMA (10) | 46.37 | Sell |
| SMA (20) | 47 | Sell |
| EMA (20) | 46.97 | Sell |
| SMA (50) | 48.43 | Sell |
| EMA (50) | 48.15 | Sell |
| SMA (100) | 49.53 | Sell |
| EMA (100) | 49.23 | Sell |
| SMA (200) | 50.8 | Sell |
| EMA (200) | 50.32 | Sell |

### Oscillators — summary: **Neutral**

| Indicator | Value | Signal |
| --- | --- | --- |
| RSI (14) | 41.24 | Neutral |
| MACD (12,26,9) | -0.77 | Sell |
| Stochastic (14,3,3) | 26.55 | Neutral |
| ADX (14) | 41.24 | Buy |
| Williams %R (14) | -80.1 | Buy |
| ATR (14) | 1.89 | High Volatility |
| ROC (12) | -3.77 | Sell |
| Stoch RSI (14) | 35.36 | Neutral |
| UO (7,14,28) | 43.04 | Neutral |

## Filings & Documents

### Exchange Filings & Announcements

| Date | Document |
| --- | --- |
| 2026-08-27 | [Compliance Under Regulation 36 Of The SEBI (Listing Obligations And Disclosures Requirements) Regulations 2015 (The Listing Regulations)](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=f76a2088-1149-4582-a757-99a45614618c.pdf) |
| 2026-08-25 | [Announcement under Regulation 30 (LODR)-Newspaper Publication](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=c370f5b8-e6ee-4830-af0c-791239835530.pdf) |
| 2026-08-24 | [Board Meeting Outcome for Outcome Of The Board Meeting Held On Monday 24Th August 2026](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=cc9cc461-95e0-4d68-ad56-c8600f883833.pdf) |
| 2026-08-24 | [Announcement under Regulation 30 (LODR)-Change in Management](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=0df83913-8c11-4c57-b3df-37728878d12e.pdf) |
| 2026-08-24 | [Announcement under Regulation 30 (LODR)-Resignation of Director](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=821a346e-f34e-4c57-bc62-49da4eded101.pdf) |
| 2026-08-24 | [49Th Annual General Meeting Of The Company Will Be Held On Tuesday 22Nd Day Of September 2026 At 04:00 P.M. (IST) Through Video Conferencing/ Other Audio Visual Means.](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=972d5851-8637-4089-a94e-c276e1f51aac.pdf) |
| 2026-08-24 | [Reg. 34 (1) Annual Report.](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=667c1785-0e01-48b5-98b8-7fdae1a8d7ab.pdf) |
| 2026-08-18 | [Announcement under Regulation 30 (LODR)-Allotment](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=5d46aee8-8ee4-49a4-a35e-6f21d98a0f3c.pdf) |
| 2026-08-18 | [Announcement Under Regulation 30 Of SEBI (LODR) Regulations 2015](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=b173e5c8-8147-47a9-b86e-5932d8623573.pdf) |
| 2026-08-13 | [Announcement under Regulation 30 (LODR)-Newspaper Publication](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=117f7a58-690f-4667-902e-ed69e52a9a54.pdf) |

### Other Documents

| Date | Document |
| --- | --- |
| 9 Jan - Certificate under Regulation. 74(5) of SEBI DP Act 2018 for the Quarter ended 31st December, 2025. | [Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations, 2018 9 Jan - Certificate under Regulation. 74(5) of SEBI DP Act 2018 for the Quarter ended 31st December, 2025.](https://www.bseindia.com/xml-data/corpfiling/AttachHis/a95ac0bf-4fb0-4415-8d6c-21b41e00ac57.pdf) |
| 9 Apr - On 31 March 2026, Eiko Lifesciences was not a Large Corporate under SEBI debt rules. | [Non Applicability Of Annual Disclosure As Per SEBI Circular - Fund Raising By Issuance Of Debt Securities By Large Corporates. 9 Apr - On 31 March 2026, Eiko Lifesciences was not a Large Corporate under SEBI debt rules.](https://www.bseindia.com/xml-data/corpfiling/AttachHis/405ca963-874a-488e-b90e-b86385266068.pdf) |
| 8 Apr - Certificate under Regulation 74(5) of SEBI (Depositories and Participants) Regulations 2018 for the quarter and year ended on 31st March, 2026 received from M/s. Bigshare … | [Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations, 2018 8 Apr - Certificate under Regulation 74(5) of SEBI (Depositories and Participants) Regulations 2018 for the quarter and year ended on 31st March, 2026 received from M/s. Bigshare …](https://www.bseindia.com/xml-data/corpfiling/AttachHis/85b78585-c98f-4cc9-9d8f-11466dbdbc80.pdf) |
| 30 Jan - Newspaper publication of Un-audited Financial results (standalone & Consolidated) for Quarter and Nine- Months ended on 31st December, 2025. | [Announcement under Regulation 30 (LODR)-Newspaper Publication 30 Jan - Newspaper publication of Un-audited Financial results (standalone & Consolidated) for Quarter and Nine- Months ended on 31st December, 2025.](https://www.bseindia.com/xml-data/corpfiling/AttachHis/af48dd8a-e526-4da2-8983-cc9258aeca72.pdf) |
| 29 Jan - Unaudited Q3/9M FY26 results (31 Dec 2025): consolidated 9M revenue INR 3,521.01 lakhs; profit INR 382.75 lakhs | [Board Meeting Outcome for Outcome Of Board Meeting Dated 29Th January, 2026 29 Jan - Unaudited Q3/9M FY26 results (31 Dec 2025): consolidated 9M revenue INR 3,521.01 lakhs; profit INR 382.75 lakhs](https://www.bseindia.com/xml-data/corpfiling/AttachHis/24314f6b-9f55-4035-9120-d75bd4c3795d.pdf) |
| 27 Feb - Of allotment of 2,01,605 number of equity shares pursuant to exercise of options under PPL - ESOP Plan 2021 | [Announcement under Regulation 30 (LODR)-Allotment of ESOP / ESPS 27 Feb - Of allotment of 2,01,605 number of equity shares pursuant to exercise of options under PPL - ESOP Plan 2021](https://www.bseindia.com/xml-data/corpfiling/AttachHis/af3e34da-8241-4112-baba-d4afcd504b25.pdf) |
| 26 Feb - Lenus Finvest allotted 175,000 shares and 150,000 warrants on 24 Feb 2026; promoter stake becomes 17.71%. | [Disclosures under Reg. 29(2) of SEBI (SAST) Regulations, 2011 26 Feb - Lenus Finvest allotted 175,000 shares and 150,000 warrants on 24 Feb 2026; promoter stake becomes 17.71%.](https://www.bseindia.com/xml-data/corpfiling/AttachHis/389BFEEC_144E_48FF_8B7D_49900072E0E6_121525.pdf) |
| 24 Feb - PPL scored 76; included in S&P Global Sustainability Yearbook 2026, top 2%, sole Indian fertilizer. | [Announcement under Regulation 30 (LODR)-Press Release / Media Release 24 Feb - PPL scored 76; included in S&P Global Sustainability Yearbook 2026, top 2%, sole Indian fertilizer.](https://www.bseindia.com/xml-data/corpfiling/AttachHis/6241cff1-aeb7-407e-a305-66d44080f195.pdf) |
| 24 Feb - Allotment of 625,000 shares at Rs55 and 2,950,000 warrants; immediate proceeds Rs7.49 crore. Eiko 24Feb2026 | [Announcement under Regulation 30 (LODR)-Allotment 24 Feb - Allotment of 625,000 shares at Rs55 and 2,950,000 warrants; immediate proceeds Rs7.49 crore. Eiko 24Feb2026](https://www.bseindia.com/xml-data/corpfiling/AttachHis/707930ca-3d55-4f31-92ec-0b55366b85a6.pdf) |
| 16 Jan - Board meeting on 29 Jan 2026 to approve Q3 FY2026 unaudited standalone and consolidated results; trading window closed. | [Board Meeting Intimation for Meeting Scheduled For Quarterly Results For The Quarter Ended 31St December, 2025 16 Jan - Board meeting on 29 Jan 2026 to approve Q3 FY2026 unaudited standalone and consolidated results; trading window closed.](https://www.bseindia.com/xml-data/corpfiling/AttachHis/c0f58b91-39cc-4fe5-914c-eda390ebfc72.pdf) |

### Earnings Call Documents

| Date | Document |
| --- | --- |
| Nov 2022 | [Concall - Nov 2022](https://www.bseindia.com/xml-data/corpfiling/AttachHis/ccaa6f8f-0fdd-4c96-ae32-d5816e5265c8.pdf) |
| Nov 2020 | [Concall - Nov 2020](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=6a11a85d-229b-4d8a-876e-7e8282115158.pdf) |
| Nov 2020 | [Concall - Nov 2020](https://www.bseindia.com/xml-data/corpfiling/AttachHis/6a11a85d-229b-4d8a-876e-7e8282115158.pdf) |
| May 2025 | [Concall - May 2025](https://www.bseindia.com/xml-data/corpfiling/AttachHis/cdc3b1aa-1277-4074-8834-8cb480bf3b24.pdf) |
| May 2023 | [Concall - May 2023](https://www.bseindia.com/xml-data/corpfiling/AttachHis/d5a4b555-fb67-45e8-9847-e775052fb000.pdf) |
| Jul 2021 | [Concall - Jul 2021](https://www.bseindia.com/xml-data/corpfiling/AttachHis/bc8729f0-3b42-4256-a4be-bcd4901fd0c0.pdf) |
| Feb 2026 | [Concall - Feb 2026](https://www.bseindia.com/xml-data/corpfiling/AttachHis/b76ae507-313c-4732-a14a-5a3d45fbc1c9.pdf) |
| Feb 2023 | [Concall - Feb 2023](https://www.bseindia.com/xml-data/corpfiling/AttachHis/a7283987-beee-4fa5-b8b6-d3fbd172d6d5.pdf) |
| Feb 2021 | [Concall - Feb 2021](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=a134d193-7550-4fa3-a380-989cdec802da.pdf) |
| Feb 2021 | [Concall - Feb 2021](https://www.bseindia.com/xml-data/corpfiling/AttachHis/a134d193-7550-4fa3-a380-989cdec802da.pdf) |

### Results & Financial Statements

| Date | Document |
| --- | --- |
| 2025-05-14 | [Results For Quarter And Year Ended 31St March 2025](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=db56d384-aab3-49c3-8401-57ab929034c5.pdf) |
| 2025-02-12 | [Financial Results For Quarter And Nine Months Ended 31St December 2024](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=c044fc6b-54ef-439b-ac91-d2e642f393d9.pdf) |
| 2024-10-19 | [Unaudited Financials Results For September 2024](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=7daf7968-40ea-4326-89d4-cfec8b843492.pdf) |
| 2024-08-13 | [Financial Results](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=8a5b9fcf-dca2-469e-bb5a-52ddfbecbf38.pdf) |
| 2024-05-13 | [Audited Financial Results Of The Company For The Quarter And Year Ended 31St March 2024 Along With Auditor'S Report Duly Signed By The Auditor Of The Company.](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=f80376a0-4d02-4793-8e13-53b4f699a128.pdf) |
| 2024-02-08 | [Financial Results For Quarter And Nine Months Ended 31St December,2023](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=c50c69a8-80f2-45bf-8bd1-46529cda5a67.pdf) |
| 2023-11-08 | [Financial Results For Quarter And Half Year Ended 30Th September, 2023](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=a5aa48a0-f637-40e6-8ab7-605163c89335.pdf) |
| 2023-07-11 | [Board Meeting Outcome for Board Meeting Outcome To Consider And Approve Unaudited Financial Results For Quarter Ending 30Th June 2023](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=c6bef388-777b-4ab8-8e89-4783fdb41f44.pdf) |
| 2023-05-09 | [Board Meeting Outcome for Outcome Of Board Meeting Of Eiko Lifesciences Limited Held On May 09, 2023](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=e70ee7b1-9a8c-4e90-9f8f-9e11598d222e.pdf) |
| 2023-05-09 | [Financial Results For Quarter And Year Ended March 31, 2023](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=734b24b3-105a-4137-9af2-65d56b7fdbef.pdf) |

### Annual Reports

| Date | Document |
| --- | --- |
| from bse | [Financial Year 2025 from bse](https://www.bseindia.com/xml-data/corpfiling/AttachHis/592024ea-8fa3-4b96-acb2-b9fac84b3044.pdf) |
| from bse | [Annual Report 2025 from bse](https://www.bseindia.com/xml-data/corpfiling/AttachHis/7fc796f1-049c-41c7-bfa5-4d12bb8f29e6.pdf) |
| from bse | [Financial Year 2024 from bse](https://www.bseindia.com/xml-data/corpfiling/AttachHis/9c834f1e-bfc1-412e-9a44-57b20b3d4594.pdf) |
| from bse | [Annual Report 2024 from bse](https://www.bseindia.com/xml-data/corpfiling/AttachHis/d689021a-b7c2-4f4a-9012-b37c820e933b.pdf) |
| from bse | [Financial Year 2023 from bse](https://www.bseindia.com/xml-data/corpfiling/AttachHis/68779a27-ba5c-427a-a98c-5eb74fb029a1.pdf) |
| from bse | [Annual Report 2023 from bse](https://www.bseindia.com/xml-data/corpfiling/AttachHis/409745c0-0609-4e41-844a-45a26784d18a.pdf) |
| from bse | [Financial Year 2022 from bse](https://www.bseindia.com/bseplus/AnnualReport/543530/74431543530.pdf) |
| from bse | [Annual Report 2022 from bse](https://www.bseindia.com/bseplus/AnnualReport/540204/73065540204.pdf) |
| from bse | [Annual Report 2021 from bse](https://www.bseindia.com/bseplus/AnnualReport/540204/69908540204.pdf) |
| from bse | [Annual Report 2020 from bse](https://www.bseindia.com/bseplus/AnnualReport/540204/66936540204_10_09_20.pdf) |

### Investor Presentations

| Date | Document |
| --- | --- |
| 2023-05-09 | [Announcement under Regulation 30 (LODR)-Investor Presentation](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=d5a4b555-fb67-45e8-9847-e775052fb000.pdf) |
| 2021-07-30 | [Announcement under Regulation 30 (LODR)-Investor Presentation](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=bc8729f0-3b42-4256-a4be-bcd4901fd0c0.pdf) |

---

Provenance differs by section. Financial statements, shareholding and filings are as reported in company disclosures to NSE/BSE/SEBI. Price, volume and 52-week levels are exchange market data. Technical indicators are computed by Tapetide from daily closing prices. The Tapetide Score is Tapetide's own analysis. Analyst ratings are third-party estimates, not company statements. All figures are for research and information only and are not investment advice. Generated 2026-09-13T18:37:08.471Z.